| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
The Indian company, Wockhardt Limited, was founded nearly four decades ago,
and today claims its place amongst the country's top research and technology
oriented pharmaceutical companies. This report provides an insight into the
company, reviewing its current business structure and activities.
Wockhardt employs some 3,500 people, and has a multi-disciplinary research and
development programme employing over 900 scientists. Wockhardt claims itself
to be the 24th largest wealth creator in India, and ranked amongst the 50 most
valuable companies in the country. Wockhardt is listed on the Bombay Stock
Exchange, the National Stock Exchange and the Luxembourg Stock Exchange.
Around half of Wockhardt's sales are from Europe and the United States.
Wockhardt has a strong presence in the United Kingdom, which is the company's
second largest market behind India. Wockhardt has made a number of
acquisitions of UK companies over the last few years. Wockhardt has also made
recent acquisitions in Germany, and has created a sales and marketing force in
the US to bring focus to its US presence.
With regard to foreign markets, Wockhardt is in the process of transforming
itself from a predominantly bulk API producer to a finished formulations
producer. The company has filed a number of ANDAs in the United States, and
also filed Drug Master Files and European Certificates of Suitability.
However, Wockhardt is also developing a presence in the biogenerics market,
and was the first Asian company to launch its own recombinant insulin product,
Wosulin. Wockhardt has started exporting its biotechnology products to Eastern
Europe, and is building a biotech park which has been designed to cater to
global markets.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- Wockhardt ANDA Approvals, 2002-2005.
- Recent product approvals
- Ranitidine
- Zonisamide
- Cefuroxime axetil
- Famotidine
- Insulin
- FINANCIAL RESULTS
- Latest Yearly Results
- Financial results, 2001 - 2005 (Rs millions)
- Latest Quarterly Results
- MAJOR DEVELOPMENTS
- Pharmaceutical plants
- Barotiwala, India
- Luton, United Kingdom
- Aurangabad, India
- FDA inspections
- Joint Ventures
- Mergers, acquisitions and agreements
- Li-Taka Pharmaceuticals
- esparma GmbH
- CP Pharmaceuticals Ltd
- Ranbaxy
- Eisai
- Bayer
- Merind Ltd
- Wallis Laboratories
- Wockhardt Rhein Biopharm
- CONTACT DETAILS
|
